What question did this study set out to answer?

To determine the synovial expression of GM-CSFRα in patients with inflammatory arthritis and evaluate the therapeutic efficacy of anti-GM-CSFRα antibody blockade in preclinical arthritis models.

June 17, 2014Annals of the Rheumatic DiseasesOpen Access

Preclinical characterisation of the GM-CSF receptor as a therapeutic target in rheumatoid arthritis

View Full Paper

Ask AI

Bookmark

Authors

DGDorothee GrevenAmsterdam UMC Location University of Amsterdam ECE. Suzanne CohenAstraZeneca (Singapore)DGDaniëlle M. GerlagUCB Pharma (United Kingdom)

Discussion

Member takes

Implication

Preclinical study reveals that targeting the GM-CSF receptor reduces joint inflammation in murine arthritis models, highlighting its therapeutic potential for rheumatoid and psoriatic arthritis.

Key Points

To determine the synovial expression of GM-CSFRα in patients with inflammatory arthritis and evaluate the therapeutic efficacy of anti-GM-CSFRα antibody blockade in preclinical arthritis models.
Quantified GM-CSFRα expression on CD68+ and CD163+ macrophages in synovial biopsy tissue from patients with rheumatoid arthritis, psoriatic arthritis, osteoarthritis, and healthy controls.
Assessed the therapeutic impact of CAM-3003, an anti-GM-CSFR antibody, in DBA/1 mice with collagen-induced arthritis alongside pharmacokinetic and pharmacodynamic evaluations in CD1(ICR) and BALB/c mice.
Synovial GM-CSFRα expression on CD68+ and CD163+ macrophages was significantly higher in patients with rheumatoid arthritis and psoriatic arthritis than in osteoarthritis and healthy controls.
CAM-3003 administration resulted in a dose-dependent reduction in clinical arthritis scores and synovial F4/80+ macrophage infiltration in collagen-induced arthritis.
Treatment with CAM-3003 effectively blocked recombinant GM-CSF-induced peripheral blood monocyte and neutrophil margination in BALB/c mice.

Cite This Study

Greven et al. (2014) studied this question.

synapsesocial.com/papers/6a821bf7e9dda39dfc46be89 https://doi.org/10.1136/annrheumdis-2014-205234

View Full Paper

Ask AI

Bookmark

Implication

Preclinical study reveals that targeting the GM-CSF receptor reduces joint inflammation in murine arthritis models, highlighting its therapeutic potential for rheumatoid and psoriatic arthritis.